Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

PTN

Palatin Technologies Inc

Dec 26 • 09:37AM ET

0.9750

Dollar change -0.0150
Percentage change -1.52	%

Healthcare • Biotechnology • USA • AMEX

Peers: ACHV ATOS XBIO CTXR LBPH LPTX SCYX AKTX DBVT CNTX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.97	Insider Own	3.89%	Shs Outstand	19.55M	Perf Week	30.00%
Market Cap	19.06M	Forward P/E	-	EPS next Y	-	Insider Trans	-0.64%	Shs Float	18.79M	Perf Month	-11.36%
Income	-32.35M	PEG	-	EPS next Q	-0.42	Inst Own	8.19%	Short Float	5.30%	Perf Quarter	2.91%
Sales	2.38M	P/S	8.01	EPS this Y	17.82%	Inst Trans	33.66%	Short Ratio	2.51	Perf Half Y	-48.68%
Book/sh	-0.39	P/B	-	EPS next Y	-	ROA	-441.31%	Short Interest	1.00M	Perf Year	-70.45%
Cash/sh	0.12	P/C	8.01	EPS next 5Y	-	ROE	-269476.55%	52W Range	0.68 - 5.65	Perf YTD	-75.50%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-82.74%	Beta	0.92
Dividend TTM	-	Quick Ratio	0.26	Sales past 5Y	148.40%	Gross Margin	67.30%	52W Low	43.38%	ATR (14)	0.12
Dividend Ex-Date	-	Current Ratio	0.26	EPS Y/Y TTM	8.34%	Oper. Margin	-1339.44%	RSI (14)	51.16	Volatility	16.55% 14.66%
Employees	30	Debt/Eq	-	Sales Y/Y TTM	-60.85%	Profit Margin	-1357.06%	Recom	1.00	Target Price	17.00
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	18.52%	Payout	-	Rel Volume	1.26	Prev Close	0.99
Sales Surprise	-	EPS Surprise	23.53%	Sales Q/Q	-100.00%	Earnings	Nov 14 BMO	Avg Volume	396.43K	Price	0.98
SMA20	2.70%	SMA50	-5.66%	SMA200	-34.80%	Trades		Volume	33,615	Change	-1.52%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-05-15	Reiterated	Canaccord Genuity	Buy	$4 → $6
Jan-12-15	Reiterated	ROTH Capital	Buy	$6 → $4
May-23-12	Initiated	Noble Financial	Buy
Jan-23-07	Initiated	Next Generation	Buy	$5

Dec-20-24 07:41AM	Palatin reports positive Phase 2b results in diabetic nephropathy (TipRanks) +12.55%
Dec-19-24 07:30AM	Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy (PR Newswire) +14.67%
Dec-16-24 07:30AM	Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds (PR Newswire) -5.03%
Nov-25-24 07:30AM	Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis (PR Newswire) +14.58%
Nov-15-24 05:24AM	Q1 2025 Palatin Technologies Inc Earnings Call (Thomson Reuters StreetEvents) -12.69%
02:15AM	Loading…
02:15AM	Palatin Technologies Inc (PTN) Q1 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue ... (GuruFocus.com)
Nov-14-24 07:30AM	Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results (PR Newswire) -10.08%
Nov-08-24 09:57AM	Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024 (PR Newswire) +12.07%
Nov-04-24 07:30AM	Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek 2024 (PR Newswire)
Oct-31-24 07:30AM	Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity (PR Newswire)
Oct-24-24 07:30AM	Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium (PR Newswire)
Oct-23-24 07:30AM	Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium (PR Newswire)
Oct-07-24 04:15PM	Palatin Receives Notice of Non-Compliance from NYSE American (PR Newswire)
Oct-02-24 06:54AM	Q4 2024 Palatin Technologies Inc Earnings Call (Thomson Reuters StreetEvents) -6.82%
03:00AM	Palatin Technologies Inc (PTN) Q4 2024 Earnings Call Transcript Highlights: Strategic Moves and ... (GuruFocus.com)
07:30AM	Loading…
Oct-01-24 07:30AM	Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones (PR Newswire)
Sep-30-24 09:01AM	Palatin Technologies Inc (PTN) Q4 2024 Earnings Report Preview: What To Expect (GuruFocus.com) +6.40%
Sep-26-24 07:30AM	Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results (PR Newswire)
Sep-09-24 07:30AM	Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones (PR Newswire)
Aug-28-24 07:30AM	FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED) (PR Newswire) +9.40%
Aug-23-24 04:52AM	Palatin Technologies doses first subject in Phase II obesity treatment trial (Clinical Trials Arena)
Aug-22-24 07:30AM	First Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity (PR Newswire)
Jun-21-24 08:00AM	Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds (PR Newswire)
04:32AM	Palatin initiates Bremelanotide-PDE5i Phase II trial for ED (Clinical Trials Arena)
Jun-20-24 07:30AM	Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED) (PR Newswire) -9.18%
Jun-13-24 06:52AM	Palatin Technologies commences Phase II study of obesity treatment (Clinical Trials Arena)
Jun-12-24 07:30AM	Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity (PR Newswire) +6.49%
May-20-24 12:00PM	Palatin Technologies (PTN) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
May-16-24 03:05AM	Palatin Technologies Inc (PTN) (Q3 2024) Earnings Call Transcript Highlights: Navigating ... (GuruFocus.com)
01:46AM	Q3 2024 Palatin Technologies Inc Earnings Call (Thomson Reuters StreetEvents)
07:30AM	Loading…
May-15-24 07:30AM	Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update (PR Newswire) -14.11%
May-09-24 07:30AM	Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024 (PR Newswire) +14.63%
May-02-24 07:30AM	Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity (PR Newswire) +9.63%
Apr-30-24 07:30AM	Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024 (PR Newswire)
Apr-14-24 03:00PM	10 Micro-Cap Healthcare Stocks Insiders Are Buying (Insider Monkey)
Apr-09-24 08:59AM	Palatin (PTN) Up 15% on Results From Dry Eye Disease Study (Zacks)
Apr-08-24 12:02PM	Palatin Technologies Eyes Growing $6B Dry Eye Disease Market With Late-Stage Study Data (Benzinga) +14.77%
07:30AM	Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024 (PR Newswire)
Feb-28-24 07:30AM	Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED) (PR Newswire) -38.29%
Feb-16-24 10:00AM	Palatin Technologies, Inc. (AMEX:PTN) Q2 2024 Earnings Call Transcript (Insider Monkey)
12:55AM	Q2 2024 Palatin Technologies Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-15-24 07:30AM	Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update (PR Newswire) -23.91%
Feb-09-24 07:30AM	Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024 (PR Newswire) +5.72%
Feb-05-24 07:30AM	Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED) (PR Newswire) +7.67%
Feb-01-24 04:00PM	Palatin Announces Closing of $10 Million Registered Direct Offering (PR Newswire) -14.25%
Jan-30-24 08:00AM	Palatin Announces $10 Million Registered Direct Offering (PR Newswire) -10.62%
Jan-11-24 01:38PM	3 Penny Stocks to Buy to Unlock 2,500% Upside Potential (InvestorPlace)
Jan-08-24 10:33AM	Palatin Provides Corporate Update and Highlights Strategic Priorities for Calendar Year 2024 (PR Newswire) +12.73%
Jan-03-24 08:00AM	Cosette Pharmaceuticals Acquires Vyleesi (Bremelanotide Injection) from Palatin Technologies Inc. (Business Wire) -10.62%
Dec-23-23 05:00PM	Analysts Say 3 Stocks Have a Combined Upside of 3000% (InvestorPlace)
Dec-20-23 07:30AM	Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million (PR Newswire)
Dec-18-23 04:15PM	Palatin Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American (PR Newswire) -8.30%
Nov-15-23 03:01PM	Palatin Technologies, Inc. (AMEX:PTN) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:29AM	Q1 2024 Palatin Technologies Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-14-23 07:30AM	Palatin Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update (PR Newswire)
Nov-09-23 07:30AM	Palatin to Report First Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on November 14, 2023 (PR Newswire)
Oct-24-23 04:50PM	Palatin Announces Closing of $5 Million Registered Direct Offering (PR Newswire)
Oct-23-23 07:30AM	Palatin Announces $5 Million Registered Direct Offering (PR Newswire) -13.75%
Oct-19-23 08:45AM	Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders (PR Newswire) +22.54%
07:30AM	Palatin Announces Preliminary Quarter Ended September 30, 2023 Vyleesi® Product Revenue Results (PR Newswire)
Oct-18-23 07:30AM	Palatin Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese Patients (PR Newswire)
Oct-16-23 07:30AM	Palatin Presents Data at the United European Gastroenterology Week 2023 Conference On PL8177 Ulcerative Colitis Treatment (PR Newswire)
Oct-13-23 04:15PM	Palatin Receives Notice of Non-Compliance from NYSE American (PR Newswire)
Oct-03-23 08:35AM	Palatin Technologies, Inc. (AMEX:PTN) Q4 2023 Earnings Call Transcript (Insider Monkey)
Sep-29-23 01:34AM	Q4 2023 Palatin Technologies Inc Earnings Call (Thomson Reuters StreetEvents)
Sep-28-23 07:30AM	Palatin Reports Fourth Quarter and Fiscal Year Ended 2023 Financial Results and Provides Corporate Update (PR Newswire) -9.09%
Sep-22-23 04:00PM	Palatin to Report Fourth Quarter and Fiscal Year End 2023 Results; Teleconference and Webcast to be held on September 28, 2023 (PR Newswire) -5.66%
Sep-07-23 04:00PM	Palatin to Present at the H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire) -7.14%
07:30AM	Palatin Completes Enrollment in Phase 3 MELODY-1 Study of PL9643 For the Treatment of Patients with Dry Eye Disease (PR Newswire)
Aug-10-23 07:30AM	Palatin Initiates Clinical Program for Bremelanotide Co-Formulated with a PDE5i for the Treatment of ED in Patients Non-Responsive to PDE5i Treatment (PR Newswire) -5.50%
Aug-08-23 07:30AM	Palatin's Vyleesi® Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study (PR Newswire) +8.20%
Aug-07-23 07:30AM	Palatin Announces Direct-to-Consumer Telehealth Partnership with UpScriptHealth for Vyleesi® (PR Newswire) +23.86%
Aug-04-23 07:30AM	Palatin to Participate in Canaccord Genuity's 43rd Annual Growth Conference (PR Newswire)
Jul-11-23 07:30AM	Palatin Announces Preliminary Fourth Quarter Fiscal 2023 Vyleesi® Product Revenue Results (PR Newswire)
May-30-23 07:30AM	Palatin Presents Preclinical Diabetic Nephropathy Data at the International Podocyte Conference (PR Newswire)
May-17-23 01:39PM	Palatin Technologies, Inc. (AMEX:PTN) Q3 2023 Earnings Call Transcript (Insider Monkey) -5.43%
01:33AM	Q3 2023 Palatin Technologies Inc Earnings Call (Thomson Reuters StreetEvents)
May-16-23 08:45AM	Palatin Technologies, Inc. (PTN) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Palatin Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update (PR Newswire)
May-15-23 09:05AM	Alimera Sciences (ALIM) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +17.19%
May-11-23 05:25PM	TELA Bio, Inc. (TELA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:15PM	Palatin to Report Third Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on May 16, 2023 (PR Newswire)
May-09-23 05:45PM	Guardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Palatin Presents PL8177 Ulcerative Colitis Data at Digestive Disease Week Annual Conference (PR Newswire)
May-08-23 04:04PM	Palatin Invites Investors to Listen to Replay of the PL9643 Dry Eye Disease Key Opinion Leader Webinar (PR Newswire) +7.62%
May-01-23 04:00PM	Palatin Technologies to Host Key Opinion Leader Webinar (PR Newswire)
Apr-27-23 07:30AM	Palatin Presents Initial Dry Eye Disease Phase 3 Clinical Data at the Association of Research in Vision and Ophthalmology 2023 Annual Conference (PR Newswire)
Apr-25-23 07:30AM	Palatin Presents Data at the Association of Research in Vision and Ophthalmology 2023 Annual Conference Regarding a Potential Treatment for Glaucoma (PR Newswire) -8.20%
Apr-19-23 07:30AM	Palatin Announces Preliminary Third Quarter Fiscal 2023 Vyleesi® Product Revenue Results (PR Newswire)
Apr-18-23 07:30AM	Pre-Clinical Data of Palatin's Melanocortin Agonist Demonstrating Therapeutic Effects in Diabetic Retinopathy and Uveitis Published in the International Journal of Molecular Sciences (PR Newswire)
Mar-02-23 07:30AM	Frontiers in Immunology Publishes Pre-Clinical Study of Palatin's Oral Formulation of PL8177 Demonstrating Therapeutic Effects in Inflammatory Bowel Disease (PR Newswire) -9.17%
Feb-28-23 07:30AM	Palatin Issued Patent on Vyleesi® (Bremelanotide Injection) For Hypoactive Sexual Desire Disorder in Patients With Controlled Hypertension (PR Newswire) +18.50%
Feb-15-23 07:30AM	Palatin Reports Second Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update (PR Newswire)
Feb-10-23 07:30AM	Palatin to Report Second Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on February 15, 2023 (PR Newswire)
Jan-26-23 05:45PM	Myovant Sciences (MYOV) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Jan-19-23 07:30AM	Palatin Initiates Enrollment in the Phase 2 Bremelanotide BREAKOUT Study in Patients with Diabetic Kidney Disease (PR Newswire)
Jan-18-23 07:30AM	Palatin Receives $4.7 Million of Non-Dilutive Funding (PR Newswire)
Jan-10-23 07:30AM	Frontiers in Immunology Publishes Pre-Clinical Study of Palatin's PL8177 Demonstrating Therapeutic Effects in Inflammatory Conditions (PR Newswire) +16.53%
Jan-05-23 07:30AM	Palatin Announces Preliminary Second Quarter Fiscal 2023 Vyleesi® Product Sales Results (PR Newswire)
Nov-14-22 08:55AM	Palatin Technologies, Inc. (PTN) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -7.71%

Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, which is used for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
WILLS STEPHEN T	Executive VP and CFO/COO	Aug 01 '24	Sale	1.66	4,999	8,274	235,456	Aug 02 05:01 PM
DEVEER ROBERT K JR	Director	Apr 11 '24	Buy	2.12	6,000	12,703	40,845	Apr 11 04:45 PM
DEVEER ROBERT K JR	Director	Mar 06 '24	Sale	2.00	11,700	23,434	34,845	Mar 07 05:02 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PTN

Palatin Technologies Inc

Upgrade your FINVIZ experience